# sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

> **NCT03552796** · PHASE1 · WITHDRAWN · sponsor: **University of Southern California**

## Conditions studied

- Recurrent Bladder Carcinoma
- Bladder Cancer Stage 0
- Bladder Cancer Stage I

## Interventions

- **OTHER:** Pharmacokinetic Study
- **BIOLOGICAL:** Recombinant EphB4-HSA Fusion Protein

## Key facts

- **NCT ID:** NCT03552796
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Budget issues
- **Last updated:** 2023-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552796, "sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03552796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*